HIV/AIDS Subpopulation

Value Based Payment Quality Measure Set
Measurement Year 2017

  • Measure Set is also available in Portable Document Format (PDF)

Updated July 14, 2017                     NYS Medicaid Value Based Payment

The 2017 HIV/AIDS Subpopulation quality measure set was created in collaboration with the HIV/AIDS Subpopulation Clinical Advisory Group (CAG) and the New York State (NYS) Value Based Payment (VBP) Workgroup. The measure set is closely aligned with existing measures sets used in the Delivery System Reform Incentive Payment (DSRIP) Program and the Quality Assurance Reporting Requirements (QARR) measure set. The HIV/AIDS measure set is intended to encourage providers to meet high standards of patient–centered clinical care and care coordination across multiple care settings throughout the HIV/AIDS care episode.

The measure set includes measures classified by category based on an assessment of reliability, validity, and feasibility, and according to suggested method of use (either Pay for Reporting (P4R) or Pay for Performance (P4P)).

To increase alignment with the QARR, one measure relating to statin therapy for those with diabetes has been changed since the March 2017 release of the HIV/AIDS VBP measure set. The change with updated measure steward is notated in red in the table below.


In May of 2016, the HIV/AIDS Subpopulation CAG published recommendations to the State on quality measures, data, and support required for providers to be successful. Additionally the report addressed other implementation details related to a VBP HIV/AIDS Subpopulation Arrangement. Upon receiving the CAG recommendations, the State conducted further feasibility review and analysis to define a final list of measures for inclusion during the 2017 VBP Measurement Year (MY). Each measure has been designated by the State as Category 1, 2, or 3 with associated recommendations for implementation and testing for future use in VBP arrangements.

    Categorizing and Prioritizing Quality Measures

Approved quality measures that are felt to be both clinically relevant, reliable and valid, and feasible.

Measures that are clinically relevant, valid, and probably reliable, but where the feasibility could be problematic. These measures should be investigated during the 2017 pilot program.

Measures that are insufficiently relevant, valid, reliable and/or feasible.

Category 1

Category 1 quality measures as identified by the HIV/AIDS Subpopulation CAG and accepted by the State are to be reported by VBP Contractors. These measures are also intended to be used to determine the amount of shared savings for which VBP contractors would be eligible1.

The State classified each Category 1 measure as either P4P or P4R:

  • P4P measures are intended to be used in the determination of shared savings amounts for which VBP Contractors are eligible. Measures can be included in both the determination of the target budget and in the calculation of shared savings for VBP Contractors.
  • P4R measures are intended to be used by the Managed Care Organizations (MCOs) to incentivize VBP Contractors for reporting data to monitor quality of care delivered to members under the VBP contract. Incentives for reporting will be based on timeliness, accuracy, and completeness of data. Measures can be reclassified from P4R to P4P through annual CAG and State review or as determined by the MCO and VBP Contractor.

Categories 2 and 3

Category 2 measures have been accepted by the State based on agreement of measure importance, validity, and reliability, but flagged as presenting concerns regarding implementation feasibility. These measures will be further investigated in the VBP pilots. The State requires that VBP Pilots select and report a minimum of two Category 2 measures per VBP arrangement (or have a State and Plan approved alternative). VBP Pilot participants will be expected to share meaningful feedback on the feasibility of Category 2 measures when the CAGs reconvene. The State will discuss measure testing approach, data collection, and reporting requirements with VBP pilots at a future date.

Measures designated as Category 3 were identified as unfeasible at this time or as presenting additional concerns including accuracy or reliability when applied to the attributed member population for the HIV/AIDS Subpopulation arrangement. Several measures in the original CAG report were removed for this reason and therefore no longer in the Category 1 or 2 measure list. These measures will not be tested in VBP pilots or included in VBP at this time.


The measures and State determined classifications provided on the following pages are recommendations for MY 2017. Note that measure classification is a State recommendation and implementation is to be determined between the MCO and VBP Contractor.

Measure sets and classifications are considered dynamic and will be reviewed annually. Updates will include additions, deletions, reclassification of measure category, and reclassification from P4R to P4P based on experience with measure implementation in the prior year. During 2017, the CAGs and the VBP Workgroup will re–evaluate measures and provide recommendations for MY 2018.

The Category 1 and 2 measure set listed in the tables below includes a subset of the Integrated Primary Care (IPC) Measure Set as determined by the State to be relevant to the HIV/AIDS subpopulation2. These tables represent the complete HIV/AIDS measure set for MY 2017.

Category 1

The Category 1 table displays the complete Category 1 HIV/AIDS Subpopulation Measure set, arranged alphabetically, and includes measure title, measure steward, the National Quality Forum (NQF) number and/or other measure identifier (where applicable), and State determined classification for measure use.

Measure Measure Steward Measure Identifier Classification
Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder Centers for Medicare & Medicaid Services (CMS) NQF 1880 P4P
Adherence to Statins for Individuals with Diabetes Mellitus * CMS NQF 0545 P4R
Antidepressant Medication Management – Effective Acute Phase Treatment & Effective Continuation Phase Treatment National Committee for Quality Assurance (NCQA) NQF 0105 P4P
Breast Cancer Screening NCQA NQF 2372 P4P
Cervical Cancer Screening NCQA NQF 0032 P4P
Colorectal Cancer Screening NCQA NQF 0034 P4P
Comprehensive Diabetes Care: All Three Tests (HbA1c, dilated eye exam, and medical attention for nephropathy) NCQA NQF #s 0055, 0062, 0057 P4P
Comprehensive Diabetes Care: Eye Exam (retinal) Performed NCQA NQF 0055 P4P
Comprehensive Diabetes Care: Foot Exam NCQA NQF 0056 P4R
Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Control (<8.0%) NCQA NQF 0575 P4R
Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) Poor Control (>9.0%) NCQA NQF 0059 P4P
Comprehensive Diabetes Care: Hemoglobin A1c (HbA1c) testing [performed] NCQA NQF 0057 P4P
Comprehensive Diabetes Care: Medical Attention for Nephropathy NCQA NQF 0062 P4P
Controlling High Blood Pressure NCQA NQF 0018 P4P
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications NCQA NQF 1932 P4P
HIV Viral Load Suppression Health Resources and Services Administration (HRSA) NQF 2028 P4P
Initiation and Engagement of Alcohol and other Drug Dependence Treatment (IET) NCQA NQF 0004 P4P
Initiation of Pharmacotherapy for Alcohol Dependence NYS Office of Alcoholism and Substance Abuse Services (OASAS) P4R
Initiation of Pharmacotherapy for Opioid Use Disorder NYS OASAS P4P
Linkage to HIV Medical Care HRSA P4R
Medication Management for People With Asthma (ages 5 – 64) – 50 % and 75% of Treatment Days Covered NCQA NQF 1799 P4P
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow– Up Plan CMS NQF 0421 P4R
Preventive Care and Screening: Influenza Immunization American Medical Association Physician Consortium for Performance Improvement (AMA PCPI) NQF 0041 P4R
Preventive Care and Screening: Screening for Clinical Depression and Follow–Up Plan CMS NQF 0418 P4R
Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention AMA PCPI NQF 0028 P4R
Proportion of Patients with HIV/AIDS that have a Potentially Avoidable Complication during a Calendar Year Altarum Institute (Formerly HCI3) P4R
Sexually Transmitted Diseases: Screening for Chlamydia, Gonorrhea, and Syphilis NCQA NQF 0409 P4P
Statin Therapy for Patients with Cardiovascular Disease NCQA P4R
Statin Therapy for Patients with Diabetes** NCQA P4R
Substance Abuse Use Screening NYS Department of Health (DOH) AIDS Institute Health Resources Services Administration, HIV/AIDS Bureau P4R
Use of spirometry testing in the assessment and diagnosis of COPD NCQA NQF 0577 P4R

*Measure substituted with NCQA measure ´Statin Therapy for Patients with Diabetes´. See above.
**Measure is part of the 2017 QARR measure set and replaces ´Adherence to Statins for Individuals with Diabetes Mellitus´. See above.

Category 2

The Category 2 table displays the complete Category 2 HIV/AIDS Subpopulation Measure set and includes measure title, measure steward, and the NQF number and/or other measure identifier (where applicable). All Category 2 measures are classified as P4R in MY 2017.

Measure Measure Steward Measure Identifier
Asthma: Assessment of Asthma Control – Ambulatory Care Setting The American Academy of Allergy, Asthma & Immunology (AAAAI)
Continuing Engagement in Treatment (CET) Alcohol and other Drug Dependence NYS OASAS
Continuity of Care (CoC) from Detox or Inpatient Rehab to a lower level of SUD treatment (within 14 days) Continuity of Care (CoC) within 14 Days of Discharge from Any Level of SUD Inpatient Care NYS OASAS
Diabetes Screening NYS DOH AIDS Institute
Hepatitis C Screening HRSA
Housing Status HRSA
Lung Function/Spirometry Evaluation (Asthma) AAAAI
Medical Case Management: Care Plan HRSA
Patient Self–Management and Action Plan (Asthma) AAAAI
Prescription of HIV Antiretroviral Therapy HRSA NQF 2083
Sexual History Taking: Anal, Oral, and Genital NYS DOH AIDS Institute
Use of Imaging Studies for Low Back Pain NCQA NQF 0052
Utilization of Pharmacotherapy for Alcohol Dependence NYS OASAS
Utilization of Pharmacotherapy for Opioid Use Disorder NYS OASAS


1. A Path toward Value Based Payment: New York State Roadmap for Medicaid Payment Reform. Annual Update. June 2016.  1
2. The IPC measure set is the same set that will be used for the Total Care for the General Population (TCGP) arrangement in 2017. Therefore, this is referred to as the TCGP/IPC measure set in other VBP related documents.  2